207 related articles for article (PubMed ID: 23661254)
21. Modulation of MMP-2 and MMP-9 secretion by cytokines, inducers and inhibitors in human glioblastoma T-98G cells.
Roomi MW; Kalinovsky T; Rath M; Niedzwiecki A
Oncol Rep; 2017 Mar; 37(3):1907-1913. PubMed ID: 28112361
[TBL] [Abstract][Full Text] [Related]
22. Modulation of human renal cell carcinoma 786-0 MMP-2 and MMP-9 activity by inhibitors and inducers in vitro.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Med Oncol; 2006; 23(2):245-50. PubMed ID: 16720925
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of cell invasion and MMP production by a nutrient mixture in malignant liposarcoma cell line SW-872.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Med Oncol; 2007; 24(4):394-401. PubMed ID: 17917088
[TBL] [Abstract][Full Text] [Related]
24. Involvement of matrix metalloproteinase 1 and urokinase-type plasminogen activator in the PKCα-p38 MAPK pathway-mediated progression of human liver cancer cells.
Ye JC; Hsieh YS; Chen PN; Liu JY; Hsieh YH
Drug Dev Res; 2023 Jun; 84(4):767-776. PubMed ID: 37005497
[TBL] [Abstract][Full Text] [Related]
25. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase.
Park MJ; Park IC; Hur JH; Kim MS; Lee HC; Woo SH; Lee KH; Rhee CH; Hong SI; Lee SH
J Neurosurg; 2002 Jul; 97(1):112-8. PubMed ID: 12134900
[TBL] [Abstract][Full Text] [Related]
26. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
27. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
Siddique K; Yanamandra N; Gujrati M; Dinh D; Rao JS; Olivero W
Int J Oncol; 2003 Feb; 22(2):289-94. PubMed ID: 12527924
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells.
Halder SK; Osteen KG; Al-Hendy A
Hum Reprod; 2013 Sep; 28(9):2407-16. PubMed ID: 23814095
[TBL] [Abstract][Full Text] [Related]
29. Role of matrix metalloproteinase (MMP) 2 and MMP-9 in soft tissue sarcoma.
Yang HK; Jeong KC; Kim YK; Jung ST
Clin Orthop Surg; 2014 Dec; 6(4):443-54. PubMed ID: 25436070
[TBL] [Abstract][Full Text] [Related]
30. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA
Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase (MMP) induction and inhibition at different doses of recombinant tissue plasminogen activator following experimental stroke.
Burggraf D; Martens HK; Dichgans M; Hamann GF
Thromb Haemost; 2007 Nov; 98(5):963-9. PubMed ID: 18000599
[TBL] [Abstract][Full Text] [Related]
32. Expression of matrix metalloproteinase-2, -9, -14, and tissue inhibitors of metalloproteinase-1, -2, -3 in the endometrium and placenta of rhesus monkey (Macaca mulatta) during early pregnancy.
Wang H; Li Q; Shao L; Zhu C
Biol Reprod; 2001 Jul; 65(1):31-40. PubMed ID: 11420220
[TBL] [Abstract][Full Text] [Related]
33. Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells.
Uchima Y; Sawada T; Nishihara T; Maeda K; Ohira M; Hirakawa K
Pancreas; 2004 Aug; 29(2):123-31. PubMed ID: 15257104
[TBL] [Abstract][Full Text] [Related]
34. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
de Bart AC; Quax PH; Löwik CW; Verheijen JH
J Bone Miner Res; 1995 Sep; 10(9):1374-84. PubMed ID: 7502710
[TBL] [Abstract][Full Text] [Related]
35. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
Kim IS; Yang WS; Kim CH
Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
[TBL] [Abstract][Full Text] [Related]
36. [Regulation of matrix-degrading enzymes in gynecologic cancer tissues and cells].
Kikkawa F
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):618-22. PubMed ID: 8808829
[TBL] [Abstract][Full Text] [Related]
37. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases and their inhibitors in Fuchs endothelial corneal dystrophy.
Xu I; Thériault M; Brunette I; Rochette PJ; Proulx S
Exp Eye Res; 2021 Apr; 205():108500. PubMed ID: 33617849
[TBL] [Abstract][Full Text] [Related]
39. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.
Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF
Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222
[TBL] [Abstract][Full Text] [Related]
40. Expression and activation of proteases in co-cultures.
Paduch R; Kandefer-Szerszeń M
Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
